Table 1.

Donor and patient characteristics according to transplantation arm

Bone marrow (n = 118)Peripheral blood (n = 109)
Donor age, y 44  (13-74) 43  (17-67)  
Patient age, y 44  (19-64) 45  (19-64)  
CMV-seronegative patient and donor 40  (34%) 30  (28%)  
CML 55  (47%) 54  (49%)  
 CP-1 49  (42%) 46  (42%)  
 > CP-1, AP 6  (5%) 8  (7%)  
AML 43  (36%) 39  (36%)  
 CR-1 33  (28%) 29  (27%)  
 > CR-1 9  (8%) 9  (8%)  
MDS 20  (17%) 16  (15%)  
Early disease* 87  (74%) 78  (72%)  
Advanced disease 31  (26%) 31  (28%) 
Bone marrow (n = 118)Peripheral blood (n = 109)
Donor age, y 44  (13-74) 43  (17-67)  
Patient age, y 44  (19-64) 45  (19-64)  
CMV-seronegative patient and donor 40  (34%) 30  (28%)  
CML 55  (47%) 54  (49%)  
 CP-1 49  (42%) 46  (42%)  
 > CP-1, AP 6  (5%) 8  (7%)  
AML 43  (36%) 39  (36%)  
 CR-1 33  (28%) 29  (27%)  
 > CR-1 9  (8%) 9  (8%)  
MDS 20  (17%) 16  (15%)  
Early disease* 87  (74%) 78  (72%)  
Advanced disease 31  (26%) 31  (28%) 

Data are presented as median (range) or n (%).

CP-1 indicates first chronic phase; AP, accelerated phase; and CR-1, first complete remission.

*

Early disease: AML CR-1, CML CP-1, refractory anemia, and refractory anemia with ringed sideroblasts.

Advanced disease: AML beyond CR-1, CML beyond CP-1 and AP, refractory anemia with excess blasts, and refractory anemia with excess blasts in transformation.

One patient with AML for whom disease status at transplantation was not known.

or Create an Account

Close Modal
Close Modal